A Randomised, Double Blind, Placebo Controlled, Multicentre, Cross Over Proof of Concept Study to Investigate the Efficacy and Safety of Pre Emptive Administration of Repeated, Oral Doses of VA111913 TS for the Alleviation of Dysmenorrhoea.
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2015
At a glance
- Drugs VA 111913 (Primary)
- Indications Dysmenorrhoea
- Focus Proof of concept; Therapeutic Use
- Sponsors Vantia Therapeutics
- 15 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.